Steven Leonard Chapman Sells 71,932 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 71,932 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total value of $16,885,317.68. Following the transaction, the chief executive officer directly owned 217,354 shares in the company, valued at approximately $51,021,677.96. This represents a 24.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $373,650.00.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The stock was sold at an average price of $229.08, for a total value of $881,499.84.
• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The stock was sold at an average price of $238.07, for a total transaction of $1,047,508.00.
• On Monday, November 3rd, Steven Leonard Chapman sold 160,703 shares of Natera stock. The shares were sold at an average price of $199.96, for a total transaction of $32,134,171.88.
• On Tuesday, October 28th, Steven Leonard Chapman sold 3,680 shares of Natera stock. The stock was sold at an average price of $191.46, for a total transaction of $704,572.80.
• On Monday, October 27th, Steven Leonard Chapman sold 2,335 shares of Natera stock. The stock was sold at an average price of $192.32, for a total transaction of $449,067.20.

Natera Stock Performance

NASDAQ NTRA opened at $241.58 on Friday. Natera, Inc. has a one year low of $125.38 and a one year high of $256.36. The company has a 50-day simple moving average of $234.18 and a 200-day simple moving average of $191.17. The firm has a market capitalization of $33.42 billion, a PE ratio of -105.49 and a beta of 1.62.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same period in the prior year, the business earned ($0.26) EPS. The business’s revenue was up 34.7% on a year-over-year basis. Equities analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Peer‑reviewed clinical validation: Natera published clinical validation of its Latitude™ tissue‑free MRD test in colorectal cancer, boosting the credibility of a higher‑value oncology product that could support future revenue and reimbursement expansion. Clinical validation article
• Positive Sentiment: Analyst support: Multiple sell‑side firms have raised price targets and the consensus remains a “Moderate Buy” with an implied target around the mid‑$200s, providing medium‑term bullish backing for the stock.
• Neutral Sentiment: Fund positioning note: A Voya MidCap Opportunities investor letter and related coverage highlight that lack of exposure to Natera hurt that fund’s Q4 performance — a sign NTRA was a notable outperformer for some mid‑cap portfolios but not a direct company catalyst. Voya fund note
• Neutral Sentiment: Mixed fundamentals & ownership: Recent quarter showed strong revenue growth (~35% YoY) but continued GAAP losses; institutional ownership is extremely high (~99.9%), which reduces free float and can both support and cap volatility depending on flows.
• Negative Sentiment: Clustered insider selling — material: CEO Steven Chapman, CFO Michael Burkes Brophy and other insiders executed large sales on Jan. 20–21 (CEO sale ~71.9k shares; CFO sales totaling ~61k+ shares across days), representing sizable reductions in holdings and increasing perceived near‑term supply pressure. CEO Form 4
• Negative Sentiment: Additional insider sales: Multiple smaller insider transactions (e.g., Solomon Moshkevich) were also reported, reinforcing the market perception of insider liquidity taking and adding downward pressure. InsiderTrades coverage

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. UBS Group boosted their price target on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Guggenheim boosted their target price on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Citigroup began coverage on Natera in a report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price target on the stock. Finally, Wells Fargo & Company boosted their price objective on Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus price target of $245.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Rakuten Investment Management Inc. bought a new position in shares of Natera during the 3rd quarter valued at about $34,096,000. SWS Partners boosted its holdings in Natera by 11.8% during the third quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock worth $7,572,000 after buying an additional 4,980 shares in the last quarter. Vontobel Holding Ltd. grew its position in Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock worth $1,373,000 after buying an additional 5,614 shares during the last quarter. Baird Financial Group Inc. lifted its position in shares of Natera by 277.8% during the 2nd quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock valued at $4,498,000 after acquiring an additional 19,576 shares during the last quarter. Finally, Orion Porfolio Solutions LLC boosted its stake in shares of Natera by 68.8% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock worth $2,051,000 after acquiring an additional 4,946 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.